HTL0039732 + atezolizumab

HTL0039732 + atezolizumab is a combination therapy under investigation for the treatment of advanced solid tumors. HTL0039732 is a novel, orally administered small molecule antagonist of the E-type prostanoid receptor 4 (EP4), which blocks activation by prostaglandin E2 (PGE2). By inhibiting EP4 signaling, it aims to counteract immune suppression in the tumor microenvironment and enhance anti-tumor immunity[1][5]. Atezolizumab is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors on T cells, thereby promoting immune-mediated tumor cell killing[3][6][7]. The combination seeks to synergistically enhance anti-cancer immune responses by simultaneously targeting two distinct immunosuppressive pathways. Clinical trials are ongoing in participants with advanced solid tumors[1][4].